HIV Protocols pp 355-371 | Cite as

HIV-1-Specific Cytotoxic T-Cell Assays

  • Josephine H. Cox
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 17)


Cytotoxic T-cells (CTL) provide the basis of protective immunity in many viral infections by appearing early in the immune response and becoming involved with the elimination of virus by lysis of infected cells. A considerable amount of evidence suggests that CTL may be an especially important component of the host defense against HIV-1 (1,2) . Strong CTL activity is seen early during the course of infection (3,4), in nonprogressor individuals, some of whom have been infected for a decade or more with HIV-1 (5,6) and also in some HIV-1 exposed sex workers (7) and babies (8,9) who remain HIV-1-negative.


  1. 1.
    Rowland-Jones, S. and McMichael, A. (1993) Cytotoxic T lymphocytes in HIV infection. Semin. Virol. 4, 83–94.CrossRefGoogle Scholar
  2. 2.
    Lederman, M. M. (1996) Role of cytotoxic T lymphocytes in the control of HIV-1 infection and HIV-1 disease progression. Cur. Opin. Infect. Dis. 9, 14–18.CrossRefGoogle Scholar
  3. 3.
    Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkwosky, W., Farthing, C., and Ho, D. D. (1994) Temporal association of cellular immune responses with the initial viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650–4655.PubMedGoogle Scholar
  4. 4.
    Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M., and Oldstone, M. B. A. (1994) Virus-specific CD8+ cytotoxic T lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68,6103–6110.PubMedGoogle Scholar
  5. 5.
    Harrer, T., Harrer, E., Kalams, S. A., Elbeik, T., Staprans, S. I., Feinberg, M. B., et al. (1996) Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV Type 1 infection. AIDS Res. Hum. Retrovir. 12, 585–592.PubMedCrossRefGoogle Scholar
  6. 6.
    Klein, M. R., van Baalen, C. A., Holwerda, A. M., Kerkhof Garde, S. R., Bende, R. J., Keet, I. P., et al. (1995) Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long term asymptomatics. J. Exp. Med. 181, 1365–1372.PubMedCrossRefGoogle Scholar
  7. 7.
    Rowland-Jones, S., Sutton, J., Ariyoshi, K., Dong, T., Gotch, F., McAdam, S., et al. (1995) HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1, 59–64.PubMedCrossRefGoogle Scholar
  8. 8.
    Cheynier, R., Langlade-Demoyen, P., Marescot, M. R., Blanche, S., Blondin, G., Wain-Hobson, S., et al. (1992) Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1 infected mothers. Eur. J. Immunol. 2, 2211–2217.CrossRefGoogle Scholar
  9. 9.
    Rowland-Jones, S., Nixon, D. F., Aldhous, M. C., Gotch, F., Ariyoshi, K., Hallam, N., et al. (1993) HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 341, 860–861.PubMedCrossRefGoogle Scholar
  10. 10.
    Walker, B. D., Chakrabarti, S., Moss, B., Paradis, T. J., Flynn, T., Durno, A. G., et al. (1987) HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328, 345–348.PubMedCrossRefGoogle Scholar
  11. 11.
    Hoffenbach, A., Langlade-Demoyen, P., Dadaglio, G., Vilmer, E., Michel, F., Mayaud, C, et al. (1989) Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J. Immunol. 142,452–462.PubMedGoogle Scholar
  12. 12.
    Koenig, S., Earl, P., Powell, B., Pantaleo, G., Merli, S., Moss, B., et al. (1988) Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus I (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual. Proc. Natl. Acad. Sci. USA 85, 8638–8642.PubMedCrossRefGoogle Scholar
  13. 13.
    Riviere, Y., Tanneau-Salvadori, F., Regnault, A., Lopez, O., Sansonetti, P., Guy, B., et al. (1989) Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins. J. Virol. 63, 2270–2277.PubMedGoogle Scholar
  14. 14.
    Blazevic, V., Ranki, A., and Krohn, K. J. E. (1995) Helper and cytotoxic T cell responses of HIV Type-1 infected individuals to synthetic peptides of REV. AIDS Res. and Hum. Retrovir. 11, 1335–1342.CrossRefGoogle Scholar
  15. 15.
    Nixon, D. F. and McMichael, A. J. (1991) Cytotoxic T-cell recognition of HIV proteins and peptides. AIDS 5, 1049–1059.PubMedGoogle Scholar
  16. 16.
    Hammond, S. A., Bollinger, R. C., Stanhope, P. E., Quinn, T. C., Schwartz, D., Clements, M. L., and Siliciano, R. F. (1992) Comparative clonal analysis of human immunodeficiency virus type-1 (HIV-l)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J. Exp. Med. 176, 1531–1542.PubMedCrossRefGoogle Scholar
  17. 17.
    Curiel, T. J., Wong, J. T., Gorczyca, P. F., Schooley, R. T., Walker, B. D., et al. (1993) CD4+ human immunodeficiency virus type-1 (HIV-1) envelope-specific cytotoxic T lymphocytes derived from the peripheral blood of an HIV-infected individual. AIDS Res. Hum. Retrovir. 9, 61–68.PubMedCrossRefGoogle Scholar
  18. 18.
    Ratto, S., Sitz, K. V., Scherer, A., Loomis, L. D., Cox, J. H., Redfield, R. R., and Birx, D. L. (1996) CD4+ T-lymphocyte lines developed from HIV-1 seropositive patients recognize difference epitopes within the V3 loop. J. AIDS 11, 128–136.Google Scholar
  19. 19.
    Earl, P. L. and Moss, B. (1992) Expression of proteins in mammalian cells using vaccinia. Current Protocols In Molecular Biology, vol 2 (Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K., eds.) units 15.1-18.9.Google Scholar
  20. 20.
    van Baalen, C. A., Klein, M. R., Geretti, A. M., Keet, R. I., Miedema, F., van Els, C. A., and Osterhaus, A. D. (1993) Selective in vitro expansion of HLA Class I-restricted HIV-1 gag-specific CD8+ T cells: cytotoxic T-lymphocyte epitopes and precursor rrequencies. AIDS 7, 781–786.PubMedCrossRefGoogle Scholar
  21. 21.
    Goteh, F., McAdam, S. N., Allsopp, C. E. M., Gallimore, A., Elvin, J., Kieny, M. P., et al. (1993) Cytotoxic T cells in HTV-2 seropositive Gambians. J. Immunol. 151,3361–3369.Google Scholar
  22. 22.
    McElrath, M., Siliciano, R. F., and Weinhold, K. J. (1997) HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization and quantitation. AIDS Res. Hum. Retrovir. 13, 211–216.PubMedCrossRefGoogle Scholar
  23. 23.
    Ferrari, G., Humphrey, W., McElrath, M.J., Excler, J. L., Duliege, A. M., Clements, M. L., et al. (1997). Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. P.N.A.S. 94, 1396–1401.PubMedCrossRefGoogle Scholar
  24. 24.
    Carmichael, A., Alp, N., and Borysiewicz, L. (1992) Quantitating the HIV-1 specific cytotoxic T cell response, in Cytotoxic T Cells in HIV and Other Retroviral Infections (Racz, P., Letvin N. L., and Gluckman, J. C., eds.), S. Karger, Basel, pp. 30–39.Google Scholar
  25. 25.
    Fazekas de St Groth, S. (1982) The evaluation of limiting dilution analysis. J. Immunol. Methods 49, R11–R23.PubMedCrossRefGoogle Scholar
  26. 26.
    Strijbosch, L. W. J., Does, R. J. M. M., and Buurman, W. A. (1988) Computer aided design and evaluation of limiting and serial dilution experiments. Int. J. Biomed. Comput. 23, 279–290.PubMedCrossRefGoogle Scholar
  27. 27.
    Geretti, A. M., Dings, M. E., van Els, C. A. van Baalen, C. A., Wijnholds, F. J., Borleffs, J. C., and Osterhaus, A. D. (1996) Human immunodeficiency virus Type 1 (HIV-1)-and Epstein-Barr Virus specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1 infected persons. J. Infect. Dis. 174, 34–45.PubMedGoogle Scholar
  28. 28.
    Carini, C. and Essex, M. (1994) Interleukin 2-dependent interleukin 7 activity enhances cytotoxic immune response of HIV-1-infected individuals. AIDS Res. Hum. Retrovir. 10, 121–130.PubMedCrossRefGoogle Scholar
  29. 29.
    Ferrari, G., King, K., Rathbun, K., Place, C. A., Packard, M. V., Bartlett, J. A., et al. (1995) IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp) Clin. Exp. Immunol. 101, 239–248.PubMedGoogle Scholar
  30. 30.
    Blomberg, K., Granberg, C., Hemmilä, I., and Lövgren, T. (1986) Europium-labeled target cells in an assay of natural killer cell activity. I. A novel non-radioactive method based on time-resolved fluorescence. J. Immunol. Methods 86, 225–233.PubMedCrossRefGoogle Scholar
  31. 31.
    Blomberg, K., Hautala, R., Lovgren, J., Mukkala, V. M., Lindqvist, C., and Akerman, K. (1996) Time resolved fluorimetric assay for natural killer activity using target cells labeled with a fluorescence enhancing ligand. J. Immunol. Methods 193, 199–206.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 1999

Authors and Affiliations

  • Josephine H. Cox
    • 1
  1. 1.Henry M. Jackson FoundationRockville

Personalised recommendations